OssDsign raises SEK 158 million in a private placement

Bioteknik
June 4th, 2025
Morten-Henneveld-CEO-ossdsign

OssDsign changes CEO for increased US focus

OssDsign announces that CEO Morten Henneveld will leave his position at the end of 2025 to make way for a...

30th April 2025
Strong growth for OssDsign

Strong growth for OssDsign – the share is rising

Just over a year after its strategy shift, OssDsign can summarize a strong 2024 as a pure orthobiology company. Net sales for the full year landed...

February 4
OssDsign gets extended market approval

OssDsign receives expanded FDA approval

OssDsign continues to reap success with the Catalyst bone graft. The company recently announced that it has reached the milestone of 2 treatments in...

September 20
Uppsala's life science sector continues to grow

Uppsala's life science sector continues to grow

With more than 100 companies with a combined turnover of over SEK 33 billion, life science has become the Uppsala region's largest growth industry.

December 2
Emplicure's Chairman of the Board comments on the CEO change

Emplicure's Chairman of the Board comments on the CEO change

Emplicure starts the fall with a new CEO and an approved application for a clinical pharmacokinetic study. BioStock spoke with...

7 October 2022
Anders Svensson, CFO at OssDsign

BioStock Investor Meeting: Interview with OssDsign

In connection with the BioStock Investor Meeting in Stockholm, BioStock's reporter was visited by Anders Svensson, CFO at OssDsign. Svensson...

September 29
OssDsign_AndersSvensson_BioStockInvestorMeeting

BioStock Investor Meeting: OssDsign presents

Medical technology company OssDsign develops and manufactures regenerative implants and patient-specific solutions for the treatment of bone defects. CFO Anders Svensson participated in...

September 22
BioStock Investor Meeting September 14 2022 Watch all presentations and interviews

BioStock Investor Meeting September 14

On September 14th, it was time again for the BioStock Investor Meeting, where life science companies from various therapeutic areas presented their...

August 15
Karolinska Development increases its net asset value

Karolinska Development increases its net asset value

Investment company Karolinska Development recently submitted its report for the first quarter of 2022. The company reports an increased net asset value of SEK 4,80...

3th of May 2022
Fully recruited study with OssDsign Catalyst

Fully recruited study with OssDsign Catalyst

Karolinska Development's portfolio company OssDsign has now recruited all patients to the TOP FUSION clinical study, which evaluates the effect and...

27th April 2022
OssDsign includes first patient in PROPEL

OssDsign includes first patient in the US

The KD company OssDsign is expanding its presence in the US. The company now announces that the first patient has been included in PROPEL, the company's...

5th April 2022